Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. (NASDAQ: INBRX) is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates using proprietary modular protein engineering platforms. The company's website is www.inhibrx.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Inhibrx Biosciences, Inc. does
In the company’s own words
Inhibrx Biosciences, Inc. (NASDAQ: INBRX) is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates using proprietary modular protein engineering platforms. The company's website is www.inhibrx.com.
The company operates as a standalone entity following its May 2024 separation from its former parent company, Inhibrx, Inc., through a spin-off and subsequent merger transaction with Sanofi. This separation allowed Inhibrx Biosciences to focus on its clinical-stage oncology pipeline while the INBRX-101 program for alpha-1 antitrypsin deficiency was transferred to Sanofi.
Inhibrx Biosciences' current clinical pipeline consists of two primary therapeutic candidates. Ozekibart (INBRX-109) is a tetravalent death-receptor 5 (DR5) agonist being investigated for the treatment of chondrosarcoma, Ewing sarcoma, and colorectal cancer. In October 2025, the company announced that ozekibart met its primary endpoint in the ChonDRAgon Phase 2/3 registrational trial for chondrosarcoma, demonstrating a statistically significant reduction in disease progression risk compared to placebo. INBRX-106 is a hexavalent OX40 agonist being evaluated as a single agent and in combination with pembrolizumab (KEYTRUDA) for patients with locally advanced or metastatic solid tumors, including non-small cell lung cancer and head and neck squamous cell carcinoma.
The company's competitive advantages stem from its proprietary single domain antibody (sdAb) platform and multispecific technologies that enable precise engineering of therapeutic candidates with optimized valency for target-specific agonism. The company's intellectual property estate includes 31 solely-owned patent families, 2 co-owned patent families with Regeneron Pharmaceuticals, and 2 co-owned with Poplar Therapeutics, comprising 32 issued U.S. patents, 164 issued foreign patents, and numerous pending applications across multiple jurisdictions.
Inhibrx Biosciences operates as a smaller reporting company with an experienced leadership team drawn from major pharmaceutical and biotechnology organizations including Genentech, Gilead Sciences, Merck, Novartis, Pfizer, and Roche. The company maintains in-house capabilities spanning discovery, protein engineering, cell biology, translational research, chemistry, manufacturing, clinical development, and commercialization.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- LA JOLLA, CA
- Fiscal year end
- December
- CIK
- 2007919
- SIC
- 2836
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Inhibrx Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Inhibrx Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Inhibrx Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Inhibrx Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Inhibrx Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”